Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th

Rhea-AI Summary

Bright Minds Biosciences Inc. (CSE: DRUG/OTCIQ: BMBIF) will present live at VirtualInvestorConferences.com on October 14, 2021, from 11:00 – 11:30 AM ET. CEO Ian McDonald and VP Josh Blacher will lead the presentation, allowing real-time investor interactions. For those unable to attend live, an archived webcast will be available post-event. Recent highlights include the advancement of BMB-101 to IND-enabling studies, significant seizure reduction by their proprietary 5-HT2C Agonist, and their application to list on Nasdaq.

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- BRIGHT MINDS BIOSCIENCES INC. (CSE: DRUG/OTCIQ: BMBIF), based in New York focused on new approaches to neuroscience, today announced that Ian McDonald, President & CEO and Josh Blacher, VP of Corporation Development, will present live at VirtualInvestorConferences.com on October 14^th.

DATE: October 14^th, 2021
TIME: 11:00 – 11:30 AM ET
LINK: https://bit.ly/3kObcQO

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

Recent Company Highlights

• Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022
• Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity
• Bright Minds Biosciences Announces Application to List on Nasdaq

About BRIGHT MINDS BIOSCIENCES INC.

Bright Minds is a biotechnology company dedicated to developing therapeutics to improve the lives of patients with severe and life–altering diseases. Bright Minds initially focused on new chemical entities for a variety of pain indications, seizures, and neuropsychiatric disorders. By leveraging the extensive drug discovery experience of the Bright Minds team, the Company is endeavouring to create a pipeline of best–in–class 5–HT (serotonin) medicines. While psychedelic medicines like psilocin are currently in clinical trials for the treatment of depression1, the Company's patented, lead product candidates feature next generation characteristics, such as lower or eliminated cardiac issues, improved pharmacokinetics and shorter half–life, and higher oral bioavailability. The Bright Minds molecules have been designed to offer greater safety over the first–generation serotonergic compounds, as they bind with greater selectivity to specific 5–HT receptor subtypes, thus avoiding off–target related side effects such as heart valve disease.

About Virtual Investor Conferences^®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bright-minds-biosciences-inc-to-webcast-live-at-virtualinvestorconferencescom-october-14th-301395054.html

SOURCE VirtualInvestorConferences.com

FAQ

What is the date and time of Bright Minds Biosciences' presentation at Virtual Investor Conferences?

Bright Minds Biosciences will present on October 14, 2021, from 11:00 – 11:30 AM ET.

Who will be presenting for Bright Minds Biosciences at the conference?

CEO Ian McDonald and VP of Corporation Development Josh Blacher will present for Bright Minds Biosciences.

How can I access the archived webcast of the Bright Minds presentation?

The archived webcast of the Bright Minds presentation will be available after the live event.

What notable advances has Bright Minds Biosciences made recently?

Bright Minds has advanced its lead program BMB-101 to IND-enabling studies and applied to list on Nasdaq.

What are the potential benefits of Bright Minds' therapeutic developments?

Their therapeutics aim to improve safety, efficacy, and reduce side effects compared to first-generation serotonergic compounds.